Robert Eriksson
Biographic Data
| ID | 7958751 |
|---|---|
| NAME | Robert Eriksson |
| GIVEN NAMES | Robert |
| FAMILY NAME | Eriksson |
| SIGNATURE | ERIKSSON R |
| AFFILIATIONS | Copenhagen University Hospital |
| ORCID | 0000-0002-4946-6456 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2019 |
| H-INDEX | 0 |
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
No prominent works on this page.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
Agonist (1 work) · Antipsychotic (1 work) · Biochemistry (1 work) · Bone density (1 work) · Bone mineral (1 work) · Bone remodeling (1 work) · Chemistry (1 work) · Diabetes mellitus (1 work) · Diabetes Treatment and Management (1 work) · Diet and metabolism studies (1 work)